Downs Christopher's most recent trade in Cns Pharmaceuticals Inc was a trade of 40,000 Restricted Stock Units done . Disclosure was reported to the exchange on April 8, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 40,000 | 241 | - | - | Restricted Stock Units | |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 40,000 | 201 | - | - | Option to purchase common stock | |
Cns Pharmaceuticals Inc
|
Downs Christopher | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.30 per share. | 01 Feb 2024 | 66,666 | 103,438 (0%) | 0% | 0.3 | 20,000 | Common stock |
Cns Pharmaceuticals Inc
|
Downs Christopher | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 66,666 | 94,906 | - | - | Series A Warrant to purchase common stock | |
Cns Pharmaceuticals Inc
|
Downs Christopher | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 66,666 | 161,572 | - | - | Series B Warrant to purchase common stock | |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.27 per share. | 22 Aug 2023 | 27,000 | 36,772 (0%) | 0% | 1.3 | 34,177 | Common Stock |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 521 | 9,772 (0%) | 0% | - | Common Stock | |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 521 | 28,248 | - | - | Restricted Stock Units | |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.20 per share. | 17 Apr 2023 | 3,100 | 9,251 (0%) | 0% | 3.2 | 9,920 | Common Stock |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 6,067 | 28,768 | - | - | Restricted Stock Units | |
EBET Inc
|
Christopher Downs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 6,300 | 6,300 | - | - | Common Stock | |
EBET Inc
|
Christopher Downs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 6,300 | 75,000 | - | - | Restricted Stock Units | |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 250,000 | 681,000 | - | - | Restricted Stock Units | |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.31 per share. | 11 Mar 2022 | 33,000 | 184,500 (1%) | 0% | 0.3 | 10,230 | Common Stock |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.94 per share. | 06 Dec 2021 | 5,000 | 151,500 (0%) | 0% | 0.9 | 4,702 | Common Stock |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.15 per share. | 19 Nov 2021 | 4,500 | 146,500 (0%) | 0% | 1.2 | 5,192 | Common Stock |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 131,000 | 431,000 | - | - | Option to purchase common stock (right to buy) | |
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 24 Aug 2020 | 142,000 | 142,000 (0%) | 0% | 2.0 | 289,680 | Common Stock |